We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 12

Putative class alleges pharma statements about new drug violated securities laws

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

Aveo Pharmaceuticals, Inc. and several of its executives have been targeted in a securities class action filed in a federal court in Massachusetts

PolyMedix expects to raise $25 million for antibiotic development

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 21 2013

PolyMedix, Inc. stockholders have overwhelmingly approved a reverse stock split of the company's common stock at a ratio of up to fifty-for-one

Cancer genetics IPO raises $6.9 million

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 18 2013

Rutherford, New Jersey-based Cancer Genetics, Inc., an early-stage diagnostics company that develops genomic-based, oncology tests and services, has

Biotech companies struggling in public markets

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 7 2011

While five venture-capital backed biotech companies have reportedly gone public in 2011, each has been forced to lower its offering price even before the initial public offering took place due to weakened demand

IPO proposed by n.c.-based company developing experimental medicines

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 4 2011

North Carolina-based Argos Therapeutics has filed a Securities and Exchange Commission registration relating to its proposed initial public offering of common stock to raise more than $86 million to help pay for clinical tests of an experimental treatment for kidney cancer

Bio supports new legislation reducing SEC paperwork burdens for small startups

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 7 2011

A bipartisan bill (S. 1544), introduced in early September 2011, has reportedly gained the support of Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood

IPOs sluggish in 2011 on disappointing returns

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • January 19 2012

Biotech initial public offerings (IPOs) tracked the market as a whole in 2011, with fewer filed and returns in the negative column

PROLOR Biotech to raise $75 million for clinical trials on growth hormones

  • Shook Hardy & Bacon LLP
  • -
  • Israel, USA
  • -
  • April 19 2012

In an April 6, 2012, filing with the U.S. Securities and Exchange Commission, Israel-based PROLOR Biotech, Inc. has registered the sale of common stock on the American Stock Exchange in an amount not to exceed $75 million

Aastrom biosciences announces financing deal to advance CVD treatments

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 29 2012

Aastrom Biosciences, an Ann Arbor, Michigan-based biotech startup, has announced a $40-million financing deal with large institutional investor Eastern Capital Limited

Eighth Circuit allows investor suit to proceed against pharmaceutical co

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 7 2012

The Eighth Circuit Court of Appeals has determined that investors alleging securities fraud against a pharmaceutical company which claimed in its Securities and Exchange Commission filings that it was in material compliance with Food and Drug Administration (FDA) regulations sufficiently pleaded that the claims were false or misleading

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy